Pharma major Lupin Limited (Lupin) has received approval for its colesevelam hydrochloride tablets, 625 mg, from the United States Food and Drug Administration (FDA), to market a generic equivalent of Welchol tablets, 625 mg, of Daiichi Sankyo, Inc.Colesevelam hydrochloride tablets, 625 mg, are indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia; to reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH).Colesevelam hydrochloride tablets (RLD: Welchol) had an annual sales of approximately US$ 159 million in the US (IQVIA MAT September 2020)
